Form 8-K
8-K — Century Therapeutics, Inc.
Accession: 0001104659-26-073429
Filed: 2026-06-12
Period: 2026-06-11
CIK: 0001850119
SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))
Item: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item: Submission of Matters to a Vote of Security Holders
Item: Financial Statements and Exhibits
Documents
8-K — tm2617728d1_8k.htm (Primary)
EX-3.1 — EXHIBIT 3.1 (tm2617728d1_ex3-1.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — FORM 8-K
8-K (Primary)
Filename: tm2617728d1_8k.htm · Sequence: 1
false
--12-31
0001850119
0001850119
2026-06-11
2026-06-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 11, 2026
Century Therapeutics, Inc.
(Exact name of registrant as specified in its
charter)
Delaware
001-40498
84-2040295
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification No.)
25
North 38th Street, 11th Floor
Philadelphia, Pennsylvania
19104
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code: (267) 817-5790
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol
Name
of Exchange on Which Registered
Common Stock, par value $0.0001 per share
IPSC
Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
As further described under Item 5.07 of this Current Report on this
Form 8-K, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”), and upon the recommendation of the Board
of Directors (the “Board”), the stockholders of Century Therapeutics, Inc. (the “Company”) approved a Certificate
of Amendment to the Company’s Second Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized
shares of common stock, par value $0.0001 per share (“Common Stock”, and such amendment, the “Authorized Shares Amendment”).
The Authorized Shares Amendment was previously approved by the Board, subject to stockholder approval.
The Authorized Shares Amendment was filed with the Secretary of State
of the State of Delaware on June 11, 2026. The Authorized Shares Amendment became effective on June 12, 2026.
The foregoing description of the Authorized Shares Amendment does not
purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which
is filed as Exhibit 3.1 to this Form 8-K and incorporated herein by reference.
Item 5.07
Submission of Matters to a Vote of Security Holders.
On June 11, 2026, the Company held its Annual Meeting. As of April 16,
2026, the record date for the Annual Meeting, there were 180,354,197 outstanding shares of the Company’s common stock. The Annual
Meeting was conducted virtually, and the following is a brief description of the final voting results for each of the proposals submitted
to a vote of the stockholders at the Annual Meeting, which are described in detail in the Company’s Definitive Proxy Statement on
Schedule 14A filed with the Securities Exchange Commission on April 27, 2026.
(a) Proposal 1 - Election of Class II Directors. Each
of Alessandro Riva, M.D. and Han Lee, Ph.D., M.B.A., were elected to the Company’s Board to serve as Class II directors until
the 2029 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation,
retirement, disqualification or removal, as follows:
Name
For
Withheld
Broker Non-Votes
Alessandro Riva, M.D.
96,165,182
17,582,584
21,941,333
Han Lee, Ph.D., M.B.A.
113,675,805
71,961
21,941,333
(b) Proposal 2 - Ratification of Independent Registered Public
Accountant. The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for
the 2026 fiscal year was ratified, as follows:
For
Against
Abstentions
Broker Non-Votes
135,560,408
107,111
21,578
0
(c) Proposal 3 - Approval of an amendment to the Second Amended
and Restated Certificate of Incorporation, as amended. The amendment to the Company’s Second Amended and Restated Certificate
of Incorporation, as amended, to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000 was approved,
as follows:
For
Against
Abstentions
Broker Non-Votes
117,444,445
18,150,386
94,262
0
(d) Proposal 4 - Approval of an adjournment of the Annual Meeting.
The adjournment of the Annual Meeting to the extent there were insufficient votes to approve Proposal 3 was approved, but such an adjournment
was not necessary in light of the approval of Proposal 3 at the Annual Meeting. The adjournment was approved, as follows:
For
Against
Abstentions
Broker Non-Votes
117,181,181
18,419,826
88,087
0
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No.
Document
3.1
Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation, as amended, of Century Therapeutics, Inc.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CENTURY THERAPEUTICS, INC.
By:
/s/ Brent Pfeiffenberger, Pharm.D.
Name:
Brent Pfeiffenberger, Pharm.D.
Title:
President, Chief Executive Officer and Chairman of the Board of Directors
Date: June 12, 2026
EX-3.1 — EXHIBIT 3.1
EX-3.1
Filename: tm2617728d1_ex3-1.htm · Sequence: 2
Exhibit 3.1
CERTIFICATE OF AMENDMENT
TO THE
CERTIFICATE OF INCORPORATION
OF
CENTURY THERAPEUTICS, INC.
Century
Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under the provisions of the General
Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that:
1. The name of this corporation is Century Therapeutics, Inc. The Corporation’s original Certificate
of Incorporation was filed with the Secretary of State of the State of Delaware on February 25, 2021. Pursuant to Section 242
of the DGCL, this Certificate of Amendment (this “Amendment”) amends certain provisions of the Company’s Second
Amended and Restated Certificate of Incorporation, as amended (the “Charter”).
2. This Amendment has been approved and duly adopted by the Corporation’s Board of Directors and stockholders
in accordance with the provisions of Section 242 of the DGCL.
3. Article IV of the Charter is hereby amended and restated in its entirety as follows:
Article IV
Capital
Stock
The
total number of shares of capital stock which the Corporation shall have authority to issue is 460,000,000 of which (i) 450,000,000
shares shall be a class designated as common stock, par value $0.0001 per share (the “Common Stock”), and (ii) 10,000,000
shares shall be a class designated as undesignated preferred stock, par value $0.0001 per share (the “Undesignated Preferred
Stock”).
Except as otherwise
provided in any certificate of designations of any series of Undesignated Preferred Stock, the number of authorized shares of the class
of Common Stock or Undesignated Preferred Stock may from time to time be increased or decreased (but not below the number of shares of
such class outstanding) by the affirmative vote of the holders of a majority in voting power of the outstanding shares of capital stock
of the Corporation irrespective of the provisions of Section 242(b)(2) of the DGCL.
The powers, preferences
and rights of, and the qualifications, limitations and restrictions upon, each class or series of stock shall be determined in accordance
with, or as set forth below in, this Article IV.
4. This Amendment shall become effective on June 12th, 2026 at 12:01 a.m. Eastern Time.
5. Except as set forth in this Amendment, the Charter remains in full force and effect.
[Remainder of Page Intentionally
Left Blank]
IN
WITNESS WHEREOF, this Certificate of Amendment to the Certificate of Incorporation has been executed by a duly authorized officer of this
Corporation on this 11th day of June, 2026.
CENTURY THERAPEUTICS, INC.
By:
/s/
Brent Pfeiffenberger, Pharm.D.
Brent Pfeiffenberger,
Pharm.D.
President,
Chief Executive Officer and Chairman of the Board of Directors
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 7
v3.26.1
Cover
Jun. 11, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Jun. 11, 2026
Current Fiscal Year End Date
--12-31
Entity File Number
001-40498
Entity Registrant Name
Century Therapeutics, Inc.
Entity Central Index Key
0001850119
Entity Tax Identification Number
84-2040295
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
25
North 38th Street
Entity Address, Address Line Two
11th Floor
Entity Address, City or Town
Philadelphia
Entity Address, State or Province
PA
Entity Address, Postal Zip Code
19104
City Area Code
267
Local Phone Number
817-5790
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, par value $0.0001 per share
Trading Symbol
IPSC
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
true
Elected Not To Use the Extended Transition Period
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details
Name:
dei_CurrentFiscalYearEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:gMonthDayItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details
Name:
dei_EntityExTransitionPeriod
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration